Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01253681
First received: October 21, 2010
Last updated: August 6, 2014
Last verified: August 2014

October 21, 2010
August 6, 2014
November 2010
October 2012   (final data collection date for primary outcome measure)
To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers. [ Time Frame: 18 weeks of combination therapy ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01253681 on ClinicalTrials.gov Archive Site
  • To evaluate the pharmacokinetics (Cmax, AUC and Cmin) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 1 until Week 7 ] [ Designated as safety issue: No ]
  • To estimate the incidence of anti-AMG 386 antibody formation [ Time Frame: Week 1 until maximum of 1 year following first dose ] [ Designated as safety issue: Yes ]
  • To evaluate the objective response rate (ORR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled. ] [ Designated as safety issue: No ]
  • To evaluate the duration of response (DOR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled. ] [ Designated as safety issue: No ]
  • To evaluate progression-free survival (PFS) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled. ] [ Designated as safety issue: No ]
  • To evaluate the number of participants with adverse events and clinical laboratory abnormalities [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]
  • To evaluate the effect of AMG 386 on the pharmacokinetics (Cmax, AUC and Cmin) of carboplatin and paclitaxel [ Time Frame: Week 1 until Week 7 ] [ Designated as safety issue: No ]
  • To evaluate the number of participants with adverse events [ Time Frame: From date of enrollment until 30-days following last study drug administration ] [ Designated as safety issue: Yes ]
  • To evaluate the effect of AMG 386 on the Peak Plasma Concentration (Cmax) of carboplatin and paclitaxel [ Time Frame: Week 1 ] [ Designated as safety issue: No ]
  • To evaluate the Peak Plasma Concentration (Cmax) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 1 ] [ Designated as safety issue: No ]
  • To estimate the incidence of anti-AMG 386 antibody formation [ Time Frame: Week 1 until maximum of 1 year following first dose ] [ Designated as safety issue: Yes ]
  • To evaluate the objective response rate (ORR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled. ] [ Designated as safety issue: No ]
  • To evaluate the incidence of all clinical laboratory abnormalities [ Time Frame: From date of enrollment until 30-days following last study drug administration. ] [ Designated as safety issue: Yes ]
  • To evaluate the effect of AMG 386 on area under the plasma concentration versus time curve (AUC) of carboplatin and paclitaxel [ Time Frame: Week 1 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on the Minimum Plasma Concentration (Cmin) of carboplatin and paclitaxel [ Time Frame: Week 1 ] [ Designated as safety issue: No ]
  • To evaluate the area under the plasma concentration versus time curve (AUC) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 1 ] [ Designated as safety issue: No ]
  • To evaluate the Minimum Plasma Concentration (Cmin) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 1 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on the Peak Plasma Concentration (Cmax) of carboplatin and paclitaxel [ Time Frame: Week 7 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on the Peak Plasma Concentration (Cmax) of carboplatin and paclitaxel [ Time Frame: Week 19 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on the Peak Plasma Concentration (Cmax) of carboplatin and paclitaxel [ Time Frame: 30-days following last study drug administration ] [ Designated as safety issue: No ]
  • To evaluate the Peak Plasma Concentration (Cmax) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 7 ] [ Designated as safety issue: No ]
  • To evaluate the Peak Plasma Concentration (Cmax) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 19 ] [ Designated as safety issue: No ]
  • To evaluate the Peak Plasma Concentration (Cmax) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: 30-days following last study drug administration ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on area under the plasma concentration versus time curve (AUC) of carboplatin and paclitaxel [ Time Frame: Week 7 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on area under the plasma concentration versus time curve (AUC) of carboplatin and paclitaxel [ Time Frame: Week 19 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on area under the plasma concentration versus time curve (AUC) of carboplatin and paclitaxel [ Time Frame: 30-days following last study drug administration ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on the Minimum Plasma Concentration (Cmin) of carboplatin and paclitaxel [ Time Frame: Week 7 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on the Minimum Plasma Concentration (Cmin) of carboplatin and paclitaxel [ Time Frame: Week 19 ] [ Designated as safety issue: No ]
  • To evaluate the effect of AMG 386 on the Minimum Plasma Concentration (Cmin) of carboplatin and paclitaxel [ Time Frame: 30-days following last study drug administration ] [ Designated as safety issue: No ]
  • To evaluate the area under the plasma concentration versus time curve (AUC) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 7 ] [ Designated as safety issue: No ]
  • To evaluate the area under the plasma concentration versus time curve (AUC) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 19 ] [ Designated as safety issue: No ]
  • To evaluate the area under the plasma concentration versus time curve (AUC) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: 30-days following last study drug administration ] [ Designated as safety issue: No ]
  • To evaluate the Minimum Plasma Concentration (Cmin) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 7 ] [ Designated as safety issue: No ]
  • To evaluate the Minimum Plasma Concentration (Cmin) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: Week 19 ] [ Designated as safety issue: No ]
  • To evaluate the duration of response (DOR) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled. ] [ Designated as safety issue: No ]
  • To evaluate progression-free survival (PFS) among subjects receiving AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: From date of first dose until the subject reaches End of Study. This will continue until 36 months after the last subject has been enrolled. ] [ Designated as safety issue: No ]
  • To evaluate the Minimum Plasma Concentration (Cmin) of AMG 386 in combination with carboplatin and paclitaxel [ Time Frame: 30-days following last study drug administration ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers. The hypothesis is that AMG 386 in combination with carboplatin and paclitaxel is safe and well tolerated.

To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers. The hypothesis is that AMG 386 in combination with carboplatin and paclitaxel is safe and well tolerated.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Carcinoma
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Primary Peritoneal Cancer
Drug: AMG 386, paclitaxel and carboplatin
15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
Experimental: AMG 386, paclitaxel and carboplatin
15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
Intervention: Drug: AMG 386, paclitaxel and carboplatin
Vergote I, Oaknin A, Baurain JF, Ananda S, Wong S, Su X, Wu B, Zhong Z, Warner D, Casado A. A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery. Eur J Cancer. 2014 Sep;50(14):2408-16. doi: 10.1016/j.ejca.2014.06.010. Epub 2014 Jul 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
27
January 2015
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female subjects more than 18 years of age with newly diagnosed high-risk FIGO Stage I (grade 3, or aneuploid grade 1 or 2) or Stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancer with an indication for first-line treatment with paclitaxel and carboplatin x 6 cycles. Subjects with pseudomyxoma, mesothelioma, adenocarcinoma of unknown primary tumor, sarcoma, or neuroendocrine histology are excluded.
  • Subjects with high-risk stage I, stage II, or stage IIIA-B must have had prior primary debulking surgery that occurred no less than 4 weeks, and no more than 12 weeks, prior to enrollment. Subjects must have recovered fully from surgery in the opinion of the investigator
  • Subjects with Stage IIIC or IV disease who have not had primary debulking surgery must have planned interval debulking surgery following 3 cycles of AMG 386, paclitaxel and carboplatin
  • Female 18 years of age or older at the time the written informed consent is obtained
  • Subjects of child-bearing potential who have not undergone a bilateral salpingo-oophorectomy and are sexually active must consent to use an accepted and effective non-hormonal method of contraception (i.e, double barrier method (eg, condom plus diaphragm) from signing the informed consent through 6 months after last dose of study drug
  • GOG Performance Status of 0 or 1
  • Life expectancy ≥ 3 months (per investigator opinion)
  • Subject plans to begin protocol-directed therapy within 7 days from enrollment
  • Adequate organ and hematological function as evidenced by the following laboratory studies prior to enrollment:

Hematological function, as follows:

  • Hemoglobin ≥ 9 g/dL
  • Absolute neutrophil count (ANC) ≥ 1.5 x 10x9/L
  • Platelet count ≥ 100 x 10x9/L and ≤ 850 x 10x9/L
  • PTT or aPTT ≤ 1.5 x ULN per institutional laboratory range and INR ≤ 1.5

Renal function, as follows:

  • Urinary protein quantitative value of ≤ 30 mg/dL in urinalysis or ≤ 1+ on dipstick, unless quantitative protein is < 1000 mg in a 24 hour urine sample
  • Creatinine clearance > 40 mL/min per 24-hr urine collection or calculated according to the Cockcroft-Gault formula

Hepatic function, as follows:

  • AST and ALT ≤ 2.5 x ULN per institutional laboratory range (or ≤ 5 x ULN if liver metastases are present)
  • Total bilirubin ≤ 1.5x institutions' ULN Nutritional
  • Albumin ≥ 2.8 g/dL

Exclusion Criteria:

  • Prior use of anticancer therapy or experimental therapy for epithelial ovarian, primary peritoneal or fallopian tube cancers
  • Previous abdominal and/or pelvic external beam radiotherapy
  • Subjects believed to be a higher than average risk of bowel perforation. This includes current symptoms of partial or complete bowel obstruction, recent (within 6 months) history of fistula or bowel perforation, subjects requiring total parenteral nutrition and continuous hydration
  • History of arterial or venous thromboembolism within 12 months prior to enrollment
  • History of clinically significant bleeding within 6 months prior to enrollment
  • History of central nervous system metastasis
  • Known active or ongoing infection (except uncomplicated urinary tract infection) within 14 days prior to enrollment
  • Currently or previously treated with AMG 386, or other molecules that inhibit the angiopoietins or Tie2 receptor
  • Current or within 30 days prior to enrollment treatment with immune modulators such as systemic cyclosporine or tacrolimus
  • Prior myeloablative high-dose chemotherapy with allogeneic or autologous stem cell (or bone marrow) transplant
  • Clinically significant cardiac disease within 12 months prior to enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication or placement of percutaneous transluminal coronary angioplasty/stent
  • Uncontrolled hypertension as defined as diastolic blood pressure > 90 mmHg OR systolic blood pressure > 140 mmHg. The use of anti-hypertensive medications to control hypertension is permitted
  • Subjects with a history of prior malignancy, except:

Malignancy treated with curative intent and with no known active disease present for ≥ 3 years prior to enrollment and felt to be at low risk for recurrence by treating physician, Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of disease Adequately treated cervical carcinoma in situ without evidence of disease

  • Major surgery within 28 days prior to enrollment or still recovering from prior surgery
  • Minor surgical procedures, including placement of tunneled central venous access device, within 3 days prior to enrollment
  • History of allergic reactions to bacterially-produced proteins
  • Hypersensitivity to paclitaxel or drugs using the vehicle cremophor
  • Pregnant (ie, positive beta-human chorionic gonadotropin test) or is breast feeding or planning to become pregnant within 6 months after the end of treatment
  • Subject has known positive test(s) for human immunodeficiency virus (HIV) infection, hepatitis C virus, acute or chronic active hepatitis B infection
  • Any condition which in the investigator's opinion makes the subject unsuitable for study participation
  • Any uncontrolled concurrent illness or history of any medical condition that may interfere with the interpretation of the study results
  • Non-healing wound, ulcer (including gastrointestinal) or fracture
  • Subject has previously been enrolled onto this study
  • Subject will not be available for follow-up assessment
  • Subject has known sensitivity to any of the products to be administered during dosing
  • Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Belgium,   Spain
 
NCT01253681
20090155
No
Amgen
Amgen
Not Provided
Study Director: MD Amgen
Amgen
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP